Well, after diagnosis Gleason 4:5 T2c in March 2018, I have been on HT Triptorelin since April 2018, had 20 fractions IMRT August 2018.
I was originally planned to be on Triptorelin for 3 years. After my post RT PSA was 0.5, I discussed this with my Onco that I had read clinical studies on the difference between 18 months Vs 36 months of HT and the fact that the risk of stopping HT at 18 months was a very low risk, but the quality of life benefits were massive.
So, I get my last Triptorelin jab mid July, that will expire mid October. I have a review mid July just before the jab, so I can ask what my clinical follow up procedure will be.
Although i am looking forward to end of hot flushes and maybe return of libido (i'm only 67), I am of course naturally nervous about what the return of testosterone will have on any surviving cancer cells.
My PSA in March 2019 was 0.2, so in July at review i'm hoping for 0.1 or undetectable.
I am going to ask for PA tests in January and April 2020 to keep a close eye on my situation. But my Onco did say if my PSA rose to above 4.0 by April 2020 she would recomend I go back on HT for the rest of my natural.
So, i am really looking forward to Christmas this year, after it being a non event in 2018 as I was pretty fresh out of RT.
Any advice from members in a similar situation to me, gratefully received
Alan Bennett